FibroGen (NASDAQ:FGEN) Now Covered by StockNews.com

StockNews.com started coverage on shares of FibroGen (NASDAQ:FGEN) in a report released on Friday morning. The brokerage issued a hold rating on the biopharmaceutical company’s stock.

FGEN has been the subject of several other research reports. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 price objective on shares of FibroGen in a report on Thursday. William Blair reaffirmed a “market perform” rating on shares of FibroGen in a report on Wednesday, November 13th.

FibroGen Stock Down 8.6 %

FGEN stock opened at $0.71 on Friday. The company has a market capitalization of $71.13 million, a P/E ratio of -0.57 and a beta of 0.75. The company has a 50-day simple moving average of $0.52 and a 200 day simple moving average of $0.43. FibroGen has a fifty-two week low of $0.18 and a fifty-two week high of $2.80.

Institutional Investors Weigh In On FibroGen

Hedge funds and other institutional investors have recently bought and sold shares of the business. Geode Capital Management LLC raised its position in FibroGen by 3.1% in the third quarter. Geode Capital Management LLC now owns 1,083,521 shares of the biopharmaceutical company’s stock worth $433,000 after acquiring an additional 32,884 shares in the last quarter. JPMorgan Chase & Co. raised its position in FibroGen by 430.7% in the third quarter. JPMorgan Chase & Co. now owns 1,673,555 shares of the biopharmaceutical company’s stock worth $668,000 after acquiring an additional 1,358,194 shares in the last quarter. FMR LLC raised its position in FibroGen by 21.8% in the third quarter. FMR LLC now owns 383,258 shares of the biopharmaceutical company’s stock worth $153,000 after acquiring an additional 68,569 shares in the last quarter. Franklin Street Advisors Inc. NC raised its position in FibroGen by 100.0% in the fourth quarter. Franklin Street Advisors Inc. NC now owns 200,000 shares of the biopharmaceutical company’s stock worth $106,000 after acquiring an additional 100,000 shares in the last quarter. Finally, Assenagon Asset Management S.A. bought a new stake in FibroGen in the third quarter worth about $307,000. 72.71% of the stock is currently owned by institutional investors.

FibroGen Company Profile

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.